Testing TI-0093 for advanced HPV-16 positive cancers
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new drug, TI-0093, for people with HPV‑16 positive solid tumors (like head and neck or cervical cancer) that have come back or spread after standard treatments. The goal is to see if the drug can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor (such as head and neck or cervical cancer) that is HPV-16 positive and has come back or spread after standard treatments.
- You are between 18 and 75 years old.
- You have at least one tumor that can be seen and measured on a scan (like a CT or MRI).
- Your blood counts (white cells, platelets, hemoglobin), liver and kidney function are within certain ranges (your doctor can check these).
- You have not had a live vaccine, immunotherapy, or certain other cancer treatments within the past few weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests HRYZ-T101 injection for people whose solid cancer is HPV18-positive and who have the HLA-DRB1*0901 immune marker. It is meant for people whose cancer has returned or spread and who have few or no effective treatment options.
This trial tests a new immune cell therapy (GT201) combined with a PD-1 inhibitor for advanced head and neck cancer. It aims to see if your own immune cells, collected from your tumor, can be boosted to fight the cancer.
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
This trial tests a personalized cell therapy (TCR-T cells) designed to target HPV-16 positive cancer cells. It may be an option for people with advanced cervical, head and neck, or anal cancer who have tried standard treatments without success.
This trial tests a new treatment called SCG142 TCR-T cells for cancers caused by HPV. The therapy uses your own immune cells to fight the tumor. It may help if other treatments haven't worked or are not available.
Hear when a new HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.